An entertaining Internet program that allows Americans to see where a dollar goes after they spend it, helped scientists develop a formula for how infectious diseases spread geographically in United States.
Inspiration comes from the most unexpected places. An international team of scientists discovered a mathematical law that can be used to predict the spread of an infectious disease across the country. The key to their discovery? Wheresgeorge.com, a recreational Web site that allows people to track dollar bills by serial number.
One of the researchers, Lars Hufnagel, a post-doctoral fellow at the Kavli Institute for Theoretical Physics at the University of California, Santa Barbara, said the team was looking for a way to understand how diseases spread geographically inside a country. Airline travel routes can be used to predict international infection patterns, he explained, but domestic travel takes too many forms to successfully use any one as an indicator.
They were looking for something quantifiable that traveled the way diseases travel but was not specific to any illness, he said. The wheresgeorge data were such a good match because currency, like disease, is almost always attached to humans when it travels.
Human travel has no scale, Hufnagel said, because people frequently travel short distances, sometimes travel moderate distances, and occasionally travel long distances. But the team found that human travel in the United States could be described by a mathematical formula known as a scaling law.
Scaling laws, which look a little like logarithmic functions to the unsophisticated, are used to determine proportionality. The laws give a sense of perspective to observers, allowing them to understand variables. A simple example of scaling: Geologists often put a hammer next to a rock when they photograph it for their records. By using a hammer of constant size, the scientists can use a formula to compare the size of rocks in two different photographs.
It turns out that a simple scaling law can describe the way humans travel and predict how a disease spreads.
“The scaling law is always the same -- from a few miles up to across the country,” Hufnagel said about the formula that describes human travel. “It doesn’t depend on where in the United States you are.”
The next step, according to Hufnagel, is to couple this information about how disease spreads geographically with local infection data that demonstrate how infections spread from person to person. Such data show how many people one sick person infects.
Together these data can be used to create a model, which the team plans to test by simulating past disease epidemics and comparing their predictions to the actual event.
Although the statistical laws discovered by the wheresgeorge study are specific to the United States, Hufnagel believes the findings will translate to other developed nations with sophisticated transportation systems.
“I would be very surprised if it is different,” he said
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.